Soquelitinib not checked

Corvus Pharmaceuticals, Inc. · CPI-818

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
4 active
5 in total · 1 in the EU
Targets
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
How it’s given
“Soquelitinib 200 mg tablets will be taken by mouth two times a day”In the company’s words, NCT06561048 on ClinicalTrials.gov
Tested for
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Atopic Dermatitis and 5 more
Main trialPhase 3
“A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).”In the company’s words, NCT06561048 on ClinicalTrials.gov
Other names
CPI-818

Other drugs for Peripheral T-Cell Lymphoma, Not Otherwise Specified

All 5 drugs for Peripheral T-Cell Lymphoma, Not Otherwise Specified

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Nov 2027 Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Phase 2Recruiting Jun 2027 Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Phase 1Active, not recruiting 30 Dec 2026 A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
Phase 1Recruiting Dec 2027 Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
Phase 1Completed 28 Jan 2026 Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Soquelitinib

Following is part of Solo: you see every change to Soquelitinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in